Overview


According to FutureWise analysis the market for growth hormone deficiency in 2023 is US$ 3.74 billion, and is expected to reach US$ 6.28 billion by 2031 at a CAGR of 6.72%.

GHD may be present at birth and develop later in life. There are many possible causes, including trauma, genetics, infections, tumors, and radiation therapy. A third of these cases are not due to any obvious cause. The root cause of the problem is usually found in the pituitary gland. In some cases, it may also be due to a deficiency of other pituitary hormones. This condition is called combined pituitary hormone deficiency. Blood tests are used to diagnose growth hormone deficiency. Human growth hormone deficiency ( HHD) is a condition where there is not enough growth hormone. A person may have short stature. Small penis size may also be present in newborns. Adults could have lower muscle mass or high cholesterol. Treatment involves growth hormone substitution using synthetic human hormones. The frequency of this condition is unknown. A severe prenatal deficiency (such as congenital Hypopituitarism), of GH, can have a minimal impact on fetal development. But, congenital and prenatal deficiency can decrease the size of a male penis, in particular, if Gonadotropins have been deficient.

Micropenis is a condition that affects males. Other consequences include hypoglycemia or exaggerated jaundice, both direct and indirect Hyperbilirubinemia. As we age, the pituitary produces decreasing amounts of GH, and other hormones, especially sex steroids. Doctors can distinguish between the natural decline in GH that comes with age and the lower levels of "true deficiency". GHD in adulthood without a cause is rare. In adulthood, GH functions to maintain muscles and bone strength. It is not well understood how it affects cognition and mood. A growth hormone deficiency may be congenital, acquired in childhood, or acquired later in life. It can be either partial or total. It can be an isolated condition or it could occur alongside other pituitary hormones. The term hypopituitarism may be interchangeably used with GH deficiencies, but more often it refers to GH plus a deficiency or deficiency of at least one anterior pituitary hormone. If GH deficiency, often with other anterior pituitary deficiency, is associated with posterior hormone deficiency (usually diabetics ), it is known as Panhypopituitarism. Children who are not growing, despite normal levels of growth hormone, should not be given GH treatment. The discomfort is reduced by using pen injectors or near-painless insulin. The injection sites are the stomach, stomach, buttocks, and thigh. To avoid lipoatrophy, injection sites should be rotated every day. GH treatment can provide measurable benefits for severely GH-deficient individuals, including increased energy and strength and improved bone density. Adipose tissue may be reduced, while muscle mass could increase. Adults with hypopituitarism have a shorter life expectancy and higher cardiovascular mortality rates than the controls. However, treatment has not been shown that increases mortality. Blood lipid levels have improved. The same is true for fractures. Although measurements of bone density increase with treatment, they are not shown to be more common.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Growth Hormone Deficiency Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Growth Hormone Deficiency Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Novo Nordisk
  • Merck and Co
  • Eli Lilly and Company
  • Pfizer Inc
  • Teva Pharmaceutical
  • Novartis AG
  • Anke Biotechnology
  • Roche
  • Ipsen
  • Ferring BV

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Application

  • Growth Hormone Deficiency
  • Prader-Willi Syndrome
  • Turner Syndrome
  • Small for Gestational Age
  • Others

By Route of Administration

  • Oral
  • Intravenous
  • Intramuscular
  • Subcutaneous

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Growth Hormone Deficiency Market By Application, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Growth Hormone Deficiency Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Growth Hormone Deficiency Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Growth Hormone Deficiency Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Growth Hormone Deficiency Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Growth Hormone Deficiency
        2. Prader-Willi Syndrome
        3. Turner Syndrome
        4. Small for Gestational Age
        5. Others

  • 8.   Growth Hormone Deficiency Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Intravenous
        3. Intramuscular
        4. Subcutaneous

  • 9.   Growth Hormone Deficiency Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 10.   North America Growth Hormone Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Growth Hormone Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Growth Hormone Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Growth Hormone Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Novo Nordisk
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck and Co
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eli Lilly and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer Inc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Anke Biotechnology
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Roche
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Ipsen
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Ferring BV
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients